Literature DB >> 34213912

Enhancing the Antitumor Effect of Doxorubicin with Photosensitive Metal-Organic Framework Nanoparticles against Breast Cancer.

Qianqian Jiang1, Mengmeng Zhang1, Quanwei Sun1, Dengke Yin1,2,3, Zihua Xuan1, Ye Yang1,4,3.   

Abstract

Breast cancer is one of the most common malignant tumors in women. The existence of multiple breast cancer subtypes often leads to chemotherapy failure or the development of drug resistance. In recent years, photodynamic therapy has been proven to enhance the sensitivity of tumors to chemotherapeutic drugs. Porphyrin-based metal-organic framework (MOF) materials could simultaneously be used as carriers for chemotherapy and photosensitizers in photodynamic therapy. In this paper, doxorubicin hydrochloride (DOX) was loaded in porphyrin MOFs, and the mechanism of the synergistic effect of the DOX carriers and photodynamic therapy on breast cancer was investigated. In vitro and in vivo experiments have shown that MOFs could prolong the residence time of DOX in tumor tissues and promote the endocytosis of DOX by tumor cells. In addition, adjuvant treatment with photodynamic therapy can promote breast cancer tumors to resensitize to DOX and synergistically enhance the chemotherapy effect of DOX. Therefore, this study can provide effective development ideas for reversing drug resistance during breast cancer chemotherapy and improving the therapeutic effect of chemotherapy on breast cancer.

Entities:  

Keywords:  breast cancer; doxorubicin hydrochloride; metal−organic framework materials; photodynamic therapy

Mesh:

Substances:

Year:  2021        PMID: 34213912     DOI: 10.1021/acs.molpharmaceut.1c00249

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  2 in total

Review 1.  Combining Nanotechnology and Gas Plasma as an Emerging Platform for Cancer Therapy: Mechanism and Therapeutic Implication.

Authors:  Milad Rasouli; Nadia Fallah; Sander Bekeschus
Journal:  Oxid Med Cell Longev       Date:  2021-10-27       Impact factor: 6.543

2.  Metal-organic frameworks for hepatocellular carcinoma therapy and mechanism.

Authors:  Yingqi Feng; Wei Wu; Muzi Li
Journal:  Front Pharmacol       Date:  2022-09-26       Impact factor: 5.988

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.